Navigation Links
Encorium Group, Inc. Completes $1.6 Million Private Placement of Common Stock and Executes Warrant Exchange Agreement; Ends Discussions to Sell Encorium OY
Date:10/19/2009

statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; and (xiii) uncertainties regarding the availability of additional capital and continued listing of our common stock on Nasdaq. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31
'/>"/>
SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Encorium Group, Inc. Announces New Business Awards of $8.7 Million, Including Swine Flu (Influenza A H1N1 virus) Vaccine Trial Win;
2. Encorium Announces Receipt of Letters from Nasdaq Regarding its Second Quarter 2009 Form 10-Q Filing
3. Encorium Reports Second Quarter 2009 Financial Results
4. Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes
5. Encorium Group Updates Expected Timeframe with Respect to the Sale of its U.S. Business
6. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
7. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
8. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
9. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
10. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
11. Encorium Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- Roka Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... detection of foodborne pathogens,  today announced that Paul G. ... Lynch 2015 Health Care Conference on May 12 at 8:00am ... Wynn, Las Vegas NV. ... through the investor relations section of Roka Bioscience,s website at ...
(Date:5/5/2015)... 2015 Research and Markets ... of the "Separation Systems Market in ... Macromolecules which include protein, RNA, DNA ... broken into smaller molecules, during production of ... various advanced systems like centrifugation, liquid chromatography, ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
(Date:5/5/2015)... WASHINGTON, D.C., USA (PRWEB) May 05, 2015 ... export regulations covering a wide range of key photonics ... are hampering global competitiveness of U.S. industry. To help ... webinar on 12 May on the proposed ... governs the commodities covered by International Traffic in Arms ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4
... A2A Adenosine Receptor Agonist Approved for Use in Identifying ... ... Astellas Pharma US, Inc. today,announced the commercial availability of ... a pharmacologic,stress agent in radionuclide MPI -- a test that ...
... JOSEPH, Mich., June 24 GeneGo, Inc., ... that VTT has licensed,MetaCore(TM). VTT develops novel ... diagnostics. The focus is in investigating,mechanisms of ... and exploration of the mechanism of action ...
... 24 Pinnacle Biologics, a private,full-service pharmaceutical and ... an agreement with Chiltern International, Inc. for the,activities ... Europe., James R. Miller, President & CEO ... agreement represents a significant step in the,process of ...
Cached Biology Technology:Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI) 2Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI) 3VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics 2Pinnacle Biologics Announces Contract With Chiltern 2
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... 2, 2015 According to preliminary ... to somewhat higher than 125 MSEK. This exceeds the ... 2014 that revenues for Q1 2015 would be in ... for Q4 2014. The operating result for the first ... complete interim report will as previously communicated be published ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... in partnership with Affymetrix, Inc., have designed a chip ... varieties and suggest ways to better manage them. By ... tissue of citrus ?genes that are associated with taste, ... information useful to researchers for rectifying existing problems and ...
... Dr. Peter Sarnow and a team of Stanford University scientists ... named miR-122, in order to replicate in cultured liver cells. ... amount of hepatitis C virus RNA was reduced by approximately ... potential to develop new antiviral agents against hepatitis C, the ...
... tiny viruses to build ultra-small "nanowire" structures for use ... few genes inside these viruses, the team was able ... a functional electronic device. , The goal of the ... and Yet-Ming Chiang, is to create batteries that cram ...
Cached Biology News:UCR researchers design chip that can improve citrus varieties 2UCR researchers design chip that can improve citrus varieties 3MIT researchers build tiny batteries with viruses 2MIT researchers build tiny batteries with viruses 3
The optional fixed lens, 105 mm, is for use with the VersaDoc imaging systems for imaging small samples at high resolution....
... The UltraClean Plant DNA Kit is ... total cellular DNA from plant cells and ... this kit replaces cumbersome DNA isolation procedures ... Using the UltraClean procedure, alcohol precipitation is ...
The sample holders for gels are used to hold gels in place in the multi-sample tray I, which is used with Molecular Imager FX imaging systems....
... Direct In Situ Apoptosis Detection ... situ by the direct TUNEL ... tagged with a directly labeled ... fluorescence staining for 40 samples ...
Biology Products: